Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fortepren is an antiviral and immunomodulating agent containing sodium polyprenyl phosphate, a substance derived from the phosphorylation of polyprenols extracted from fir needles (*Abies sibirica*). Developed by GamaVetFarm Ltd, it is primarily indicated for the treatment of chronic recurrent genital herpesvirus infection (HRGVI) in adults. The drug exerts its effect by activating innate immune cells, including macrophages and dendritic cells, and stimulating the production of endogenous interferons and pro-inflammatory cytokines such as IL-1β, IL-15, IFN-γ, TNF-α, and IL-12. It is typically administered via intramuscular injection, often as a follow-up to acyclovir therapy to prolong remission and reduce relapse severity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium polyprenyl phosphate.